You have 9 free searches left this month | for more free features.

Tremelimumab

Showing 1 - 25 of 219

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Mesothelioma Trial in Durham, Houston (Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemo plus

Not yet recruiting
  • Mesothelioma
  • Durvalumab / tremelimumab
  • Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
  • Durham, North Carolina
  • +1 more
Jul 5, 2023

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
May 16, 2023

Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)

Not yet recruiting
  • Borderline Resectable Carcinoma
  • Biliary Tract Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

Hepatocellular Carcinoma Trial in Munich, Würzburg (durvalumab, tremelimumab, bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • durvalumab, tremelimumab, bevacizumab
  • Munich, Germany
  • +2 more
May 3, 2023

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Trial in Bobigny (Durvalumab/Tremelimumab in neoadjuvant

Not yet recruiting
  • BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
  • Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
  • Bobigny, France
    Hospitl Avicenne
Sep 13, 2023

Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma Trial in Hannover (Durvalumab and Tremelimumab,

Completed
  • Metastatic Adult Soft Tissue Sarcoma
  • Recurrent Adult Soft Tissue Sarcoma
  • Hannover, Germany
    Medizinische Hochschule Hannover
Jan 18, 2023

Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 18, 2023

Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)

Active, not recruiting
  • Metastatic
  • +4 more
  • Radiotherapy
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 6, 2023

Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Sep 27, 2022

Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, Tremelimumab (Cohort A

Recruiting
  • Intermediate Stage of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Oct 6, 2022

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

Recruiting
  • Hepatocellular Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Tremelimumab

Active, not recruiting
  • Urothelial Bladder Cancer
  • +2 more
  • Tremelimumab monotherapy
  • +2 more
  • San Francisco, California
  • +13 more
Jan 20, 2023

Metastatic Breast Cancer Trial in New York (Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed

Completed
  • Metastatic Breast Cancer
  • Brain radiotherapy or Stereotactic Radiosurgery
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 2, 2022

Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • +3 more
  • Durvalumab
  • +5 more
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Available
  • Unresectable Hepatocellular Carcinoma
  • (no location specified)
Aug 12, 2022

Multiple Myeloma Trial in New York (Tremelimumab, Durvalumab, Prevnar-13)

Terminated
  • Multiple Myeloma
  • Tremelimumab
  • +3 more
  • New York, New York
  • +1 more
Oct 3, 2022

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022

Hepatocellular Carcinoma Trial in Chicago, New York (TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi)

Recruiting
  • Hepatocellular Carcinoma
  • TheraSphere Y-90 glass microsphere therapy
  • +2 more
  • Washington, District of Columbia
  • +7 more
Jan 17, 2023

Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)

Recruiting
  • Cholangiocarcinoma
  • Novel combination of chemotherapy and immunotherapy
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jul 28, 2022

Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic

Not yet recruiting
  • Locally Advanced Intrahepatic Cholangiocarcinoma
  • +4 more
  • Angiography
  • +8 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Sep 22, 2023

Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7 Trial in Houston (procedure,

Completed
  • Clear Cell Renal Cell Carcinoma
  • +2 more
  • Cryosurgery
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 6, 2022

Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 Trial in Houston (biological, other,

Completed
  • Metastatic Carcinoma in the Liver
  • +4 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022